{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:47:01Z","timestamp":1792028821725,"version":"4.4.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02201-8","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:14:32Z","timestamp":1780200872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current advances in immunotherapy for KRAS-Mutant pancreatic cancer"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5318-8792","authenticated-orcid":false,"given":"Man","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8167-2054","authenticated-orcid":false,"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2400-3296","authenticated-orcid":false,"given":"Pengen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6822-9238","authenticated-orcid":false,"given":"Hongjie","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4576-7286","authenticated-orcid":false,"given":"Jianbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2621-0156","authenticated-orcid":false,"given":"Ye","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"2201_CR1","doi-asserted-by":"publisher","first-page":"1369136","DOI":"10.3389\/fmed.2024.1369136","volume":"11","author":"A Linehan","year":"2024","unstructured":"Linehan A, O\u2019Reilly M, McDermott R, et al. Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Front Med (Lausanne). 2024;11:1369136. https:\/\/doi.org\/10.3389\/fmed.2024.1369136.","journal-title":"Front Med (Lausanne)"},{"key":"2201_CR2","doi-asserted-by":"publisher","first-page":"9313","DOI":"10.3390\/ijms24119313","volume":"24","author":"E Gurreri","year":"2023","unstructured":"Gurreri E, Genovese G, Perelli L, et al. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy. Int J Mol Sci. 2023;24:9313. https:\/\/doi.org\/10.3390\/ijms24119313.","journal-title":"Int J Mol Sci"},{"key":"2201_CR3","doi-asserted-by":"publisher","first-page":"762","DOI":"10.20892\/j.issn.2095-3941.2025.0122","volume":"22","author":"N Khan","year":"2025","unstructured":"Khan N, Raza U, Ali Zaidi SA, et al. Drugging the \u2018undruggable\u2019 KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer. Cancer Biol Med. 2025;22:762\u201388. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2025.0122.","journal-title":"Cancer Biol Med"},{"key":"2201_CR4","doi-asserted-by":"publisher","first-page":"116058","DOI":"10.1016\/j.biopha.2023.116058","volume":"171","author":"M Xu","year":"2024","unstructured":"Xu M, Zhao X, Wen T, et al. Unveiling the role of KRAS in tumor immune microenvironment. Biomed Pharmacother. 2024;171:116058. https:\/\/doi.org\/10.1016\/j.biopha.2023.116058.","journal-title":"Biomed Pharmacother"},{"key":"2201_CR5","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.21.02616","volume":"40","author":"NA Ullman","year":"2022","unstructured":"Ullman NA, Burchard PR, Dunne RF, et al. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot. J Clin Oncol. 2022;40:2789\u2013805. https:\/\/doi.org\/10.1200\/JCO.21.02616.","journal-title":"J Clin Oncol"},{"key":"2201_CR6","doi-asserted-by":"publisher","first-page":"e02714","DOI":"10.1002\/advs.202502714","volume":"12","author":"J Ma","year":"2025","unstructured":"Ma J, Fu S, Tan J, et al. Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment. Adv Sci (Weinh). 2025;12:e02714. https:\/\/doi.org\/10.1002\/advs.202502714.","journal-title":"Adv Sci (Weinh)"},{"key":"2201_CR7","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.3390\/cancers14184351","volume":"14","author":"K Yamamoto","year":"2022","unstructured":"Yamamoto K, Iwadate D, Kato H, et al. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Cancers (Basel). 2022;14:4351. https:\/\/doi.org\/10.3390\/cancers14184351.","journal-title":"Cancers (Basel)"},{"key":"2201_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41575-021-00431-7","volume":"18","author":"J Encarnacion-Rosado","year":"2021","unstructured":"Encarnacion-Rosado J, Kimmelman AC. Harnessing metabolic dependencies in pancreatic cancers. Nat Rev Gastroenterol Hepatol. 2021;18:482\u201392. https:\/\/doi.org\/10.1038\/s41575-021-00431-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2201_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-024-02218-1","volume":"24","author":"Q Ma","year":"2025","unstructured":"Ma Q, Zhang W, Wu K, et al. The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy. Mol Cancer. 2025;24:14. https:\/\/doi.org\/10.1186\/s12943-024-02218-1.","journal-title":"Mol Cancer"},{"key":"2201_CR10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828\u201333. https:\/\/doi.org\/10.1097\/CJI.0b013e3181eec14c.","journal-title":"J Immunother"},{"key":"2201_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","volume":"17","author":"P Farhangnia","year":"2024","unstructured":"Farhangnia P, Khorramdelazad H, Nickho H, et al. Current and future immunotherapeutic approaches in pancreatic cancer treatment. J Hematol Oncol. 2024;17:40. https:\/\/doi.org\/10.1186\/s13045-024-01561-6.","journal-title":"J Hematol Oncol"},{"key":"2201_CR12","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.esmogo.2024.100042","volume":"4","author":"EB Faber","year":"2024","unstructured":"Faber EB, Baca Y, Xiu J, et al. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status. ESMO Gastrointest Oncol. 2024;4:100042. https:\/\/doi.org\/10.1016\/j.esmogo.2024.100042.","journal-title":"ESMO Gastrointest Oncol"},{"key":"2201_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"key":"2201_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ccell.2025.03.010","volume":"43","author":"PR Lowenstein","year":"2025","unstructured":"Lowenstein PR, Varela ML, Castro MG. The discrete charm of oncolytic viruses: Toward the finish line. Cancer Cell. 2025;43:611\u20138. https:\/\/doi.org\/10.1016\/j.ccell.2025.03.010.","journal-title":"Cancer Cell"},{"key":"2201_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","volume":"75","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Richmond A, Yan C. Harnessing the potential of CD40 agonism in cancer therapy. Cytokine Growth Factor Rev. 2024;75:40\u201356. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.11.002.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2201_CR16","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padron","year":"2022","unstructured":"Padron LJ, Maurer DM, O\u2019Hara MH, et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28:1167\u201377. https:\/\/doi.org\/10.1038\/s41591-022-01829-9.","journal-title":"Nat Med"},{"key":"2201_CR17","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1200\/JCO.21.02511","volume":"40","author":"IM Chen","year":"2022","unstructured":"Chen IM, Johansen JS, Theile S, et al. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). J Clin Oncol. 2022;40:3180\u20139. https:\/\/doi.org\/10.1200\/JCO.21.02511.","journal-title":"J Clin Oncol"},{"key":"2201_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","volume":"36","author":"GJ Weiss","year":"2018","unstructured":"Weiss GJ, Blaydorn L, Beck J, et al. Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma. Invest New Drugs. 2018;36:96\u2013102. https:\/\/doi.org\/10.1007\/s10637-017-0525-1.","journal-title":"Invest New Drugs"},{"key":"2201_CR19","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.2024.42.3_suppl.704","volume":"42","author":"V Sahai","year":"2024","unstructured":"Sahai V, Gunchick V, Paul S, et al. Tumor immune microenvironment of KRAS G12C mutated pancreatic cancer as compared to other mutations and non-cancer pancreata. J Clin Oncol. 2024;42:704. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.704.","journal-title":"J Clin Oncol"},{"key":"2201_CR20","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, McAndrews KM, LeBleu VS, et al. KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell. 2023;41:1606\u2013e208. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.002.","journal-title":"Cancer Cell"},{"key":"2201_CR21","doi-asserted-by":"publisher","first-page":"115051","DOI":"10.1016\/j.ejca.2024.115051","volume":"212","author":"J M\u2019Baloula","year":"2024","unstructured":"M\u2019Baloula J, Tougeron D, Boileve A, et al. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study. Eur J Cancer. 2024;212:115051. https:\/\/doi.org\/10.1016\/j.ejca.2024.115051.","journal-title":"Eur J Cancer"},{"key":"2201_CR22","unstructured":"W P. Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum. ESMO Congress 2024. 2024. p. Abstract 1504MO."},{"key":"2201_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/bs.acr.2023.02.003","volume":"159","author":"S Kumar","year":"2023","unstructured":"Kumar S, Singh SK, Srivastava P, et al. Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer. Adv Cancer Res. 2023;159:113\u201343. https:\/\/doi.org\/10.1016\/bs.acr.2023.02.003.","journal-title":"Adv Cancer Res"},{"key":"2201_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04299-5","author":"W Park","year":"2026","unstructured":"Park W, O\u2019Connor CA, Chou JF, et al. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04299-5.","journal-title":"Nat Med"},{"key":"2201_CR25","doi-asserted-by":"publisher","first-page":"102719","DOI":"10.1016\/j.ctrv.2024.102719","volume":"125","author":"E Brozos-Vazquez","year":"2024","unstructured":"Brozos-Vazquez E, Toledano-Fonseca M, Costa-Fraga N, et al. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection. Cancer Treat Rev. 2024;125:102719. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102719.","journal-title":"Cancer Treat Rev"},{"key":"2201_CR26","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/clinchem\/hvaf066","volume":"71","author":"JW Chun","year":"2025","unstructured":"Chun JW, Lee DE, Kim MK, et al. Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study. Clin Chem. 2025;71:993\u20131004. https:\/\/doi.org\/10.1093\/clinchem\/hvaf066.","journal-title":"Clin Chem"},{"key":"2201_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41698-025-01087-1","volume":"9","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Mai G, Zhao X, et al. Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis. NPJ Precis Oncol. 2025;9:299. https:\/\/doi.org\/10.1038\/s41698-025-01087-1.","journal-title":"NPJ Precis Oncol"},{"key":"2201_CR28","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre CA, Grimont A, Park J, et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell. 2024;42:1614\u2013e295. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.002.","journal-title":"Cancer Cell"},{"key":"2201_CR29","doi-asserted-by":"publisher","first-page":"217641","DOI":"10.1016\/j.canlet.2025.217641","volume":"618","author":"JH Jeong","year":"2025","unstructured":"Jeong JH, Shin D, Kim SY, et al. Spatial distribution and activation changes of T cells in pancreatic tumors according to KRAS mutation subtype. Cancer Lett. 2025;618:217641. https:\/\/doi.org\/10.1016\/j.canlet.2025.217641.","journal-title":"Cancer Lett"},{"key":"2201_CR30","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/jnci\/djae095JNCI","volume":"116","author":"M Fergus Keane","year":"2024","unstructured":"Fergus Keane M, BCh BAO, Joanne F. Chou,. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. JNCI. 2024;116:1429\u201338. https:\/\/doi.org\/10.1093\/jnci\/djae095 JNCI.","journal-title":"JNCI"},{"key":"2201_CR31","doi-asserted-by":"publisher","first-page":"101711","DOI":"10.1016\/j.xcrm.2024.101711","volume":"5","author":"D Yang","year":"2024","unstructured":"Yang D, Sun X, Moniruzzaman R, et al. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Cell Rep Med. 2024;5:101711. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101711.","journal-title":"Cell Rep Med"},{"key":"2201_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/path.6212","volume":"262","author":"E Michiels","year":"2024","unstructured":"Michiels E, Madhloum H, Van Lint S, et al. High-resolution and quantitative spatial analysis reveal intra-ductal phenotypic and functional diversification in pancreatic cancer. J Pathol. 2024;262:76\u201389. https:\/\/doi.org\/10.1002\/path.6212.","journal-title":"J Pathol"},{"key":"2201_CR33","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","volume":"28","author":"PA Philip","year":"2022","unstructured":"Philip PA, Azar I, Xiu J, et al. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clin Cancer Res. 2022;28:2704\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3581.","journal-title":"Clin Cancer Res"},{"key":"2201_CR34","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/cells11030398","volume":"11","author":"F Pereira","year":"2022","unstructured":"Pereira F, Ferreira A, Reis CA, et al. KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications. Cells. 2022;11:398. https:\/\/doi.org\/10.3390\/cells11030398.","journal-title":"Cells"},{"key":"2201_CR35","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Gross O, Brummer T, et al. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11:5439. https:\/\/doi.org\/10.1038\/s41467-020-19288-6.","journal-title":"Nat Commun"},{"key":"2201_CR36","doi-asserted-by":"publisher","first-page":"466","DOI":"10.21147\/j.issn.1000-9604.2025.03.13","volume":"37","author":"M Li","year":"2025","unstructured":"Li M, Zhou R, Qiu Y, et al. Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer. Chin J Cancer Res. 2025;37:466\u201386. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2025.03.13.","journal-title":"Chin J Cancer Res"},{"key":"2201_CR37","doi-asserted-by":"publisher","first-page":"10219","DOI":"10.3390\/ijms221910219","volume":"22","author":"S Hafezi","year":"2021","unstructured":"Hafezi S, Saber-Ayad M, Abdel-Rahman WM. Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. Int J Mol Sci. 2021;22:10219. https:\/\/doi.org\/10.3390\/ijms221910219.","journal-title":"Int J Mol Sci"},{"key":"2201_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","volume":"6","author":"T Tang","year":"2021","unstructured":"Tang T, Huang X, Zhang G, et al. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:72. https:\/\/doi.org\/10.1038\/s41392-020-00449-4.","journal-title":"Signal Transduct Target Ther"},{"key":"2201_CR39","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.3390\/cancers16132438","volume":"16","author":"A Argentiero","year":"2024","unstructured":"Argentiero A, Andriano A, Caradonna IC, et al. Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions. Cancers (Basel). 2024;16:2438. https:\/\/doi.org\/10.3390\/cancers16132438.","journal-title":"Cancers (Basel)"},{"key":"2201_CR40","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-021-00375-9","volume":"21","author":"SA Kerk","year":"2021","unstructured":"Kerk SA, Papagiannakopoulos T, Shah YM, et al. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat Rev Cancer. 2021;21:510\u201325. https:\/\/doi.org\/10.1038\/s41568-021-00375-9.","journal-title":"Nat Rev Cancer"},{"key":"2201_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13046-022-02273-w","volume":"41","author":"L Liu","year":"2022","unstructured":"Liu L, Huang X, Shi F, et al. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. J Exp Clin Cancer Res. 2022;41:56. https:\/\/doi.org\/10.1186\/s13046-022-02273-w.","journal-title":"J Exp Clin Cancer Res"},{"key":"2201_CR42","doi-asserted-by":"publisher","first-page":"11560","DOI":"10.3390\/ijms252111560","volume":"25","author":"A Hegazi","year":"2024","unstructured":"Hegazi A, Rager LE, Watkins DE, et al. Advancing Immunotherapy in Pancreatic Cancer. Int J Mol Sci. 2024;25:11560. https:\/\/doi.org\/10.3390\/ijms252111560.","journal-title":"Int J Mol Sci"},{"key":"2201_CR43","doi-asserted-by":"publisher","first-page":"117430","DOI":"10.1016\/j.biopha.2024.117430","volume":"179","author":"R Ni","year":"2024","unstructured":"Ni R, Hu Z, Tao R. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer. Biomed Pharmacother. 2024;179:117430. https:\/\/doi.org\/10.1016\/j.biopha.2024.117430.","journal-title":"Biomed Pharmacother"},{"key":"2201_CR44","doi-asserted-by":"publisher","first-page":"e007883","DOI":"10.1136\/jitc-2023-007883","volume":"12","author":"M Callahan","year":"2024","unstructured":"Callahan M, Amin A, Kaye FJ, et al. Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). J Immunother Cancer. 2024;12:e007883. https:\/\/doi.org\/10.1136\/jitc-2023-007883.","journal-title":"J Immunother Cancer"},{"key":"2201_CR45","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.3390\/cancers14163991","volume":"14","author":"G Fanciulli","year":"2022","unstructured":"Fanciulli G, Modica R, La Salvia A, et al. Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells? Cancers (Basel). 2022;14:3991. https:\/\/doi.org\/10.3390\/cancers14163991.","journal-title":"Cancers (Basel)"},{"key":"2201_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jare.2024.01.014","volume":"67","author":"HY Tang","year":"2025","unstructured":"Tang HY, Cao YZ, Zhou YW, et al. The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer. J Adv Res. 2025;67:253\u201367. https:\/\/doi.org\/10.1016\/j.jare.2024.01.014.","journal-title":"J Adv Res"},{"key":"2201_CR47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-023-01467-9","volume":"16","author":"J Fan","year":"2023","unstructured":"Fan J, Yu Y, Yan L, et al. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer. J Hematol Oncol. 2023;16:77. https:\/\/doi.org\/10.1186\/s13045-023-01467-9.","journal-title":"J Hematol Oncol"},{"key":"2201_CR48","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1016\/j.ymthe.2025.01.012","volume":"33","author":"G Zhong","year":"2025","unstructured":"Zhong G, Zhang X, Zhao R, et al. The high efficacy of claudin18.2-targeted CAR-T cell therapy in advanced pancreatic cancer with an antibody-dependent safety strategy. Mol Ther. 2025;33:2778\u201388. https:\/\/doi.org\/10.1016\/j.ymthe.2025.01.012.","journal-title":"Mol Ther"},{"key":"2201_CR49","doi-asserted-by":"publisher","first-page":"e010341","DOI":"10.1136\/jitc-2024-010341","volume":"13","author":"Y Jia","year":"2025","unstructured":"Jia Y, Wang Y, Zhao G, et al. Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer. J Immunother Cancer. 2025;13:e010341. https:\/\/doi.org\/10.1136\/jitc-2024-010341.","journal-title":"J Immunother Cancer"},{"key":"2201_CR50","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41416-024-02583-0","volume":"130","author":"M Hashimoto","year":"2024","unstructured":"Hashimoto M, Kuroda S, Kanaya N, et al. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. Br J Cancer. 2024;130:1187\u201395. https:\/\/doi.org\/10.1038\/s41416-024-02583-0.","journal-title":"Br J Cancer"},{"key":"2201_CR51","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"E Van Cutsem","year":"2020","unstructured":"Van Cutsem E, Tempero MA, Sigal D, et al. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020;38:3185\u201394. https:\/\/doi.org\/10.1200\/JCO.20.00590.","journal-title":"J Clin Oncol"},{"key":"2201_CR52","doi-asserted-by":"publisher","first-page":"e003254","DOI":"10.1136\/jitc-2021-003254","volume":"9","author":"M Bazan-Peregrino","year":"2021","unstructured":"Bazan-Peregrino M, Garcia-Carbonero R, Laquente B, et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J Immunother Cancer. 2021;9:e003254. https:\/\/doi.org\/10.1136\/jitc-2021-003254.","journal-title":"J Immunother Cancer"},{"key":"2201_CR53","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1078-0432.CCR-24-1660","volume":"31","author":"JCMGL Beatty","year":"2025","unstructured":"Beatty JCMGL. Facts and Hopes of CD40 Agonists in Cancer Immunotherapy. Clin Cancer Res. 2025;31:2079\u201387. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1660.","journal-title":"Clin Cancer Res"},{"key":"2201_CR54","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","volume":"27","author":"KT Byrne","year":"2021","unstructured":"Byrne KT, Betts CB, Mick R, et al. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021;27:4574\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1047.","journal-title":"Clin Cancer Res"},{"key":"2201_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.canlet.2020.11.041","volume":"499","author":"ST Muth","year":"2021","unstructured":"Muth ST, Saung MT, Blair AB, et al. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. Cancer Lett. 2021;499:99\u2013108. https:\/\/doi.org\/10.1016\/j.canlet.2020.11.041.","journal-title":"Cancer Lett"},{"key":"2201_CR56","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1158\/1535-7163.MCT-24-0330","volume":"24","author":"B Li","year":"2025","unstructured":"Li B, Gong S, Zhang N, et al. A Novel Designed Anti-PD-L1\/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity. Mol Cancer Ther. 2025;24:317\u201330. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0330.","journal-title":"Mol Cancer Ther"},{"key":"2201_CR57","doi-asserted-by":"publisher","first-page":"100562","DOI":"10.1016\/j.medj.2024.11.015","volume":"6","author":"AV Yaremenko","year":"2025","unstructured":"Yaremenko AV, Khan MM, Zhen X, et al. Clinical advances of mRNA vaccines for cancer immunotherapy. Med. 2025;6:100562. https:\/\/doi.org\/10.1016\/j.medj.2024.11.015.","journal-title":"Med"},{"key":"2201_CR58","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, Guasp P, Reiche C, et al. RNA neoantigen vaccines prime long-lived CD8(+) T cells in pancreatic cancer. Nature. 2025;639:1042\u201351. https:\/\/doi.org\/10.1038\/s41586-024-08508-4.","journal-title":"Nature"},{"key":"2201_CR59","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.tips.2024.10.009","volume":"45","author":"AG Weinstein","year":"2024","unstructured":"Weinstein AG, DeNardo DG. Targeting dendritic cells to drive PDAC immunotherapy response. Trends Pharmacol Sci. 2024;45:1095\u20136. https:\/\/doi.org\/10.1016\/j.tips.2024.10.009.","journal-title":"Trends Pharmacol Sci"},{"key":"2201_CR60","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.23.02585","volume":"42","author":"FR van \u2019t Land","year":"2024","unstructured":"van \u2018t Land FR, Willemsen M, Bezemer K, et al. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. J Clin Oncol. 2024;42:3083\u201393. https:\/\/doi.org\/10.1200\/JCO.23.02585.","journal-title":"J Clin Oncol"},{"key":"2201_CR61","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-24-3403","volume":"31","author":"P Agarwal","year":"2025","unstructured":"Agarwal P, Guo M, Munjal K, et al. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2025;31:3205\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3403.","journal-title":"Clin Cancer Res"},{"key":"2201_CR62","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","volume":"27","author":"L Zheng","year":"2021","unstructured":"Zheng L, Ding D, Edil BH, et al. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clin Cancer Res. 2021;27:1278\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2974.","journal-title":"Clin Cancer Res"},{"key":"2201_CR63","doi-asserted-by":"publisher","first-page":"e2410998","DOI":"10.1002\/adma.202410998","volume":"37","author":"X Guo","year":"2025","unstructured":"Guo X, Yang Z, Guo Z, et al. A Polymeric mRNA Vaccine Featuring Enhanced Site-Specific mRNA Delivery and Inherent STING-Stimulating Performance for Tumor Immunotherapy. Adv Mater. 2025;37:e2410998. https:\/\/doi.org\/10.1002\/adma.202410998.","journal-title":"Adv Mater"},{"key":"2201_CR64","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06063-y.","journal-title":"Nature"},{"key":"2201_CR65","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.actbio.2022.04.001","volume":"145","author":"X Wang","year":"2022","unstructured":"Wang X, Li X, Ito A, et al. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site. Acta Biomater. 2022;145:235\u201345. https:\/\/doi.org\/10.1016\/j.actbio.2022.04.001.","journal-title":"Acta Biomater"},{"key":"2201_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.omto.2022.04.002","volume":"25","author":"M Fusciello","year":"2022","unstructured":"Fusciello M, Ylosmaki E, Feola S, et al. A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella. Mol Ther Oncolytics. 2022;25:137\u201345. https:\/\/doi.org\/10.1016\/j.omto.2022.04.002.","journal-title":"Mol Ther Oncolytics"},{"key":"2201_CR67","doi-asserted-by":"publisher","first-page":"eadk1827","DOI":"10.1126\/sciadv.adk1827","volume":"10","author":"JWJGT Zhang","year":"2024","unstructured":"Zhang JWJGT. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Sci Adv. 2024;10:eadk1827. https:\/\/doi.org\/10.1126\/sciadv.adk1827.","journal-title":"Sci Adv"},{"key":"2201_CR68","doi-asserted-by":"publisher","first-page":"1277810","DOI":"10.3389\/fimmu.2023.1277810","volume":"14","author":"F Tong","year":"2023","unstructured":"Tong F, Sun Y, Zhu Y, et al. Making cold tumors hot- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report. Front Immunol. 2023;14:1277810. https:\/\/doi.org\/10.3389\/fimmu.2023.1277810.","journal-title":"Front Immunol"},{"key":"2201_CR69","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00262-024-03744-z","volume":"73","author":"Q Wang","year":"2024","unstructured":"Wang Q, Tong F, Qiao L, et al. Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical trial. Cancer Immunol Immunother. 2024;73:201. https:\/\/doi.org\/10.1007\/s00262-024-03744-z.","journal-title":"Cancer Immunol Immunother"},{"key":"2201_CR70","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(22)00066-3","volume":"23","author":"X Zhu","year":"2022","unstructured":"Zhu X, Cao Y, Liu W, et al. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23:e105\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(22)00066-3.","journal-title":"Lancet Oncol"},{"key":"2201_CR71","doi-asserted-by":"publisher","first-page":"109941","DOI":"10.1016\/j.radonc.2023.109941","volume":"190","author":"X Zhu","year":"2024","unstructured":"Zhu X, Liu W, Cao Y, et al. Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. Radiother Oncol. 2024;190:109941. https:\/\/doi.org\/10.1016\/j.radonc.2023.109941.","journal-title":"Radiother Oncol"},{"key":"2201_CR72","doi-asserted-by":"publisher","first-page":"6761","DOI":"10.1158\/1078-0432.CCR-21-0998","volume":"27","author":"H Peng","year":"2021","unstructured":"Peng H, James CA, Cullinan DR, et al. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Clin Cancer Res. 2021;27:6761\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0998.","journal-title":"Clin Cancer Res"},{"key":"2201_CR73","doi-asserted-by":"publisher","first-page":"113440","DOI":"10.1016\/j.ejca.2023.113440","volume":"196","author":"CWF van Eijck","year":"2024","unstructured":"van Eijck CWF, Strijk G, Vietsch EE, et al. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. Eur J Cancer. 2024;196:113440. https:\/\/doi.org\/10.1016\/j.ejca.2023.113440.","journal-title":"Eur J Cancer"},{"key":"2201_CR74","doi-asserted-by":"publisher","first-page":"116721","DOI":"10.1016\/j.bcp.2024.116721","volume":"232","author":"G Liu","year":"2025","unstructured":"Liu G, Yang D, Meng J, et al. The combination of gemcitabine and albumin-bound paclitaxel effectively inhibits de novo lipogenesis in pancreatic cancer cells by targeting the AMPK\/SREBP1 pathway. Biochem Pharmacol. 2025;232:116721. https:\/\/doi.org\/10.1016\/j.bcp.2024.116721.","journal-title":"Biochem Pharmacol"},{"key":"2201_CR75","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf DJ, Loree JM, Knox JJ, et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2022;13:5020. https:\/\/doi.org\/10.1038\/s41467-022-32591-8.","journal-title":"Nat Commun"},{"key":"2201_CR76","doi-asserted-by":"publisher","first-page":"188751","DOI":"10.1016\/j.bbcan.2022.188751","volume":"1877","author":"ZH Xu","year":"2022","unstructured":"Xu ZH, Wang WQ, Liu L, et al. A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Biochim Biophys Acta Rev Cancer. 2022;1877:188751. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188751.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2201_CR77","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/path.6432","volume":"266","author":"K Toriyama","year":"2025","unstructured":"Toriyama K, Masago K, Shibata N, et al. Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes. J Pathol. 2025;266:337\u201351. https:\/\/doi.org\/10.1002\/path.6432.","journal-title":"J Pathol"},{"key":"2201_CR78","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.6004\/jnccn.2022.7039","volume":"20","author":"CF Ng","year":"2022","unstructured":"Ng CF, Glaspy J, Placencio-Hickok VR, et al. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2022;20:1076\u20139. https:\/\/doi.org\/10.6004\/jnccn.2022.7039.","journal-title":"J Natl Compr Canc Netw"},{"key":"2201_CR79","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1136\/gutjnl-2012-302759","volume":"62","author":"V Heinemann","year":"2013","unstructured":"Heinemann V, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the \u2018Arbeitsgemeinschaft Internistische Onkologie\u2019 (AIO-PK0104). Gut. 2013;62:751\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2012-302759.","journal-title":"Gut"},{"key":"2201_CR80","doi-asserted-by":"publisher","first-page":"e2400684","DOI":"10.1200\/PO-24-00684","volume":"9","author":"MI Ebia","year":"2025","unstructured":"Ebia MI, Blais EM, Cui Y, et al. Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer. JCO Precis Oncol. 2025;9:e2400684. https:\/\/doi.org\/10.1200\/PO-24-00684.","journal-title":"JCO Precis Oncol"},{"key":"2201_CR81","doi-asserted-by":"publisher","first-page":"e191939","DOI":"10.1172\/JCI191939","volume":"135","author":"K Drizyte-Miller","year":"2025","unstructured":"Drizyte-Miller K, Talabi T, Somasundaram A, et al. KRAS: the Achilles\u2019 heel of pancreas cancer biology. J Clin Invest. 2025;135:e191939. https:\/\/doi.org\/10.1172\/JCI191939.","journal-title":"J Clin Invest"},{"key":"2201_CR82","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, et al. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386. https:\/\/doi.org\/10.1038\/s41392-021-00780-4.","journal-title":"Signal Transduct Target Ther"},{"key":"2201_CR83","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388:33\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2208470.","journal-title":"N Engl J Med"},{"key":"2201_CR84","doi-asserted-by":"crossref","unstructured":"Jawad Noor MFKMZ. Outcomes of KRAS G12C inhibitors in metastatic pancreatic cancer: A systematic review and meta-analysis. 2025 ASCO Annual Meeting. 2025. p. Abstract #: e16206.","DOI":"10.1200\/JCO.2025.43.16_suppl.e16206"},{"key":"2201_CR85","doi-asserted-by":"crossref","unstructured":"Pasi A, J\u00e4nne, Willemijn S, Theelen MCG. First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients(pts) with advanced\/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study. 2025 ASCO Annual Meeting. 2025. p. Abstract #: 8500.","DOI":"10.1200\/JCO.2025.43.16_suppl.8500"},{"key":"2201_CR86","doi-asserted-by":"crossref","unstructured":"Konstantin H, Dragnev. Safety and efficacy of olomorasib\u2009+\u2009immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial. 2025 ASCO Annual Meeting. 2025. p. Abstract #: 8519.","DOI":"10.1200\/JCO.2025.43.16_suppl.8519"},{"key":"2201_CR87","doi-asserted-by":"publisher","first-page":"e2302485120","DOI":"10.1073\/pnas.2302485120","volume":"120","author":"P Akkapeddi","year":"2023","unstructured":"Akkapeddi P, Hattori T, Khan I, et al. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors. Proc Natl Acad Sci U S A. 2023;120:e2302485120. https:\/\/doi.org\/10.1073\/pnas.2302485120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2201_CR88","doi-asserted-by":"publisher","first-page":"eads0239","DOI":"10.1126\/science.ads0239","volume":"389","author":"C Weller","year":"2025","unstructured":"Weller C, Burnett GL, Jiang L, et al. A neomorphic protein interface catalyzes covalent inhibition of RAS(G12D) aspartic acid in tumors. Science. 2025;389:eads0239. https:\/\/doi.org\/10.1126\/science.ads0239.","journal-title":"Science"},{"key":"2201_CR89","doi-asserted-by":"crossref","unstructured":"Zhou A. Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC). ESMO Congress 2025. 2025. p. LBA84.","DOI":"10.1016\/j.annonc.2025.09.099"},{"key":"2201_CR90","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","volume":"15","author":"AE Maciag","year":"2025","unstructured":"Maciag AE, Stice JP, Wang B, et al. Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C. Cancer Discov. 2025;15:578\u201394. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0840.","journal-title":"Cancer Discov"},{"key":"2201_CR91","doi-asserted-by":"crossref","unstructured":"al. FYTJTLLCe. GFH375 (VS-7375): An oral, selective KRAS G12D (ON\/OFF) inhibitor with potent anti-tumor efficacy. In: AACR, editor. Proceedings of the American Association for Cancer Research Annual Meeting 2024. 2024. p. 3318.","DOI":"10.1158\/1538-7445.AM2024-3318"},{"key":"2201_CR92","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, et al. EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. Cancer Discov. 2020;10:1129\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0187.","journal-title":"Cancer Discov"},{"key":"2201_CR93","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Han J, Hsu WH, et al. Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer Discov. 2025;15:162\u201378. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0489.","journal-title":"Cancer Discov"},{"key":"2201_CR94","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, et al. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024;14:2135\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0177.","journal-title":"Cancer Discov"},{"key":"2201_CR95","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12943-025-02288-9","volume":"24","author":"DSR Bandi","year":"2025","unstructured":"Bandi DSR, Nagaraju GP, Sarvesh S, et al. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Mol Cancer. 2025;24:76. https:\/\/doi.org\/10.1186\/s12943-025-02288-9.","journal-title":"Mol Cancer"},{"key":"2201_CR96","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/2159-8290.CD-24-1425","volume":"15","author":"C Broderick","year":"2025","unstructured":"Broderick C, Mezzadra R, Sisso EM, et al. A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2025;15:1717\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1425.","journal-title":"Cancer Discov"},{"key":"2201_CR97","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1158\/2159-8290.CD-24-1475","volume":"15","author":"M Orlen","year":"2025","unstructured":"Orlen M, Vostrejs WP, Sor R, et al. T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Cancer Discov. 2025;15:1697\u2013716. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1475.","journal-title":"Cancer Discov"},{"key":"2201_CR98","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381:317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med"},{"key":"2201_CR99","doi-asserted-by":"publisher","first-page":"116803","DOI":"10.1016\/j.bcp.2025.116803","volume":"234","author":"S Wang","year":"2025","unstructured":"Wang S, Huang J, Zeng T, et al. Parps in immune response: Potential targets for cancer immunotherapy. Biochem Pharmacol. 2025;234:116803. https:\/\/doi.org\/10.1016\/j.bcp.2025.116803.","journal-title":"Biochem Pharmacol"},{"key":"2201_CR100","doi-asserted-by":"publisher","first-page":"2539442","DOI":"10.1080\/2162402X.2025.2539442","volume":"14","author":"YC Shi","year":"2025","unstructured":"Shi YC, An Q, Tang N, et al. Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8(+) T cell infiltration. Oncoimmunology. 2025;14:2539442. https:\/\/doi.org\/10.1080\/2162402X.2025.2539442.","journal-title":"Oncoimmunology"},{"key":"2201_CR101","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/s41416-022-01966-5","volume":"127","author":"C Davidson","year":"2022","unstructured":"Davidson C, Taggart D, Sims AH, et al. FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer. Br J Cancer. 2022;127:1893\u2013905. https:\/\/doi.org\/10.1038\/s41416-022-01966-5.","journal-title":"Br J Cancer"},{"key":"2201_CR102","doi-asserted-by":"publisher","first-page":"111536","DOI":"10.1016\/j.isci.2024.111536","volume":"28","author":"B Zhang","year":"2025","unstructured":"Zhang B, Zhang Z, Gao J, et al. Targeting FAK improves the tumor uptake of antibody-drug conjugates to strengthen the anti-cancer responses. iScience. 2025;28:111536. https:\/\/doi.org\/10.1016\/j.isci.2024.111536.","journal-title":"iScience"},{"key":"2201_CR103","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","volume":"28","author":"A Wang-Gillam","year":"2022","unstructured":"Wang-Gillam A, Lim KH, McWilliams R, et al. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study. Clin Cancer Res. 2022;28:5254\u201362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0308.","journal-title":"Clin Cancer Res"},{"key":"2201_CR104","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.ccell.2021.07.023","volume":"39","author":"Y Wang","year":"2021","unstructured":"Wang Y, Liu S, Yang Z, et al. Anti-PD-1\/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021;39:1375\u2013e876. https:\/\/doi.org\/10.1016\/j.ccell.2021.07.023.","journal-title":"Cancer Cell"},{"key":"2201_CR105","doi-asserted-by":"publisher","first-page":"189373","DOI":"10.1016\/j.bbcan.2025.189373","volume":"1880","author":"F Gao","year":"2025","unstructured":"Gao F, Sun K, Wang S, et al. Lactate metabolism reprogramming in PDAC: Potential for tumor therapy. Biochim Biophys Acta Rev Cancer. 2025;1880:189373. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189373.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2201_CR106","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656\u201370. https:\/\/doi.org\/10.1016\/j.cell.2012.01.058.","journal-title":"Cell"},{"key":"2201_CR107","doi-asserted-by":"crossref","unstructured":"Elizabeth Auckley GY, Stephanie Yohay. MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12R alteration. 2025 ASCO Gastrointestinal Cancers Symposium. 2025. p. Abstract #: 725.","DOI":"10.1200\/JCO.2025.43.4_suppl.725"},{"key":"2201_CR108","unstructured":"Hall B. September 28,. Atebimetinib (IMM-1-104) + Modified Gemcitabine\/Nab-Paclitaxel (mGnP) Shows Extraordinary Overall Survival (OS) and Favorable Tolerability in First-Line (1L) Metastatic PDAC: Updated Phase 2 Results. Presented at PanCAN, Boston, MA (2025). Cambridge, MA: Immuneering Corporation; 2025."},{"key":"2201_CR109","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.1039\/d1tb02858h","volume":"10","author":"L Xu","year":"2022","unstructured":"Xu L, Tang S, Yang H, et al. Sustained delivery of gemcitabine via in situ injectable mussel-inspired hydrogels for the local therapy of pancreatic cancer. J Mater Chem B. 2022;10:6338\u201350. https:\/\/doi.org\/10.1039\/d1tb02858h.","journal-title":"J Mater Chem B"},{"key":"2201_CR110","doi-asserted-by":"publisher","first-page":"e2206873","DOI":"10.1002\/advs.202206873","volume":"10","author":"HC Liu","year":"2023","unstructured":"Liu HC, Davila Gonzalez D, Viswanath DI, et al. Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Adv Sci (Weinh). 2023;10:e2206873. https:\/\/doi.org\/10.1002\/advs.202206873.","journal-title":"Adv Sci (Weinh)"},{"key":"2201_CR111","doi-asserted-by":"publisher","first-page":"7133","DOI":"10.2147\/IJN.S436253","volume":"18","author":"G Qi","year":"2023","unstructured":"Qi G, Shi G, Wang S, et al. A Novel pH-Responsive Iron Oxide Core-Shell Magnetic Mesoporous Silica Nanoparticle (M-MSN) System Encapsulating Doxorubicin (DOX) and Glucose Oxidase (Gox) for Pancreatic Cancer Treatment. Int J Nanomed. 2023;18:7133\u201347. https:\/\/doi.org\/10.2147\/IJN.S436253.","journal-title":"Int J Nanomed"},{"key":"2201_CR112","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1016\/j.apsb.2022.02.007","volume":"12","author":"H Tang","year":"2022","unstructured":"Tang H, Xue Y, Li B, et al. Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma. Acta Pharm Sin B. 2022;12:3410\u201326. https:\/\/doi.org\/10.1016\/j.apsb.2022.02.007.","journal-title":"Acta Pharm Sin B"},{"key":"2201_CR113","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1021\/acs.nanolett.2c03131","volume":"22","author":"ZY Han","year":"2022","unstructured":"Han ZY, Chen QW, Fu ZJ, et al. Probiotic Spore-Based Oral Drug Delivery System for Enhancing Pancreatic Cancer Chemotherapy by Gut-Pancreas-Axis-Guided Delivery. Nano Lett. 2022;22:8608\u201317. https:\/\/doi.org\/10.1021\/acs.nanolett.2c03131.","journal-title":"Nano Lett"},{"key":"2201_CR114","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.actbio.2023.05.047","volume":"167","author":"Y Luo","year":"2023","unstructured":"Luo Y, Li C, Zhang Y, et al. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment. Acta Biomater. 2023;167:387\u2013400. https:\/\/doi.org\/10.1016\/j.actbio.2023.05.047.","journal-title":"Acta Biomater"},{"key":"2201_CR115","doi-asserted-by":"crossref","unstructured":"Pishvaian MJ, AHZCDLea. Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC) \u2013 Phase 3 Trial Interim Analysis. In: AACR, editor. Proceedings of the American Association for Cancer Research Annual Meeting 2023. 2023. p. CT084.","DOI":"10.1158\/1538-7445.AM2023-CT084"},{"key":"2201_CR116","doi-asserted-by":"publisher","first-page":"100356","DOI":"10.1016\/j.esmoop.2021.100356","volume":"7","author":"PJ Ross","year":"2022","unstructured":"Ross PJ, Wasan HS, Croagh D, et al. Results of a single-arm pilot study of (32)P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine\/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open. 2022;7:100356. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100356.","journal-title":"ESMO Open"},{"key":"2201_CR117","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3760\/cma.j.cn115667-20191014-00090","volume":"20","author":"\u7fdf\u535a\u96c5 \u6768\u91ce\u6a0a","year":"2020","unstructured":"\u6768\u91ce\u6a0a \u7fdf\u535a\u96c5. \u9f9a\u4e88\u5e0c \u4e8c\u4ee3\u6d4b\u5e8f\u5728\u80f0\u817a\u764c\u4e2d\u7684\u5e94\u7528 \u4e2d\u534e\u80f0\u817a\u75c5\u6742\u5fd7. 2020;20:393\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn115667-20191014-00090.","journal-title":"\u9f9a\u4e88\u5e0c \u4e8c\u4ee3\u6d4b\u5e8f\u5728\u80f0\u817a\u764c\u4e2d\u7684\u5e94\u7528 \u4e2d\u534e\u80f0\u817a\u75c5\u6742\u5fd7"},{"key":"2201_CR118","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.3390\/cancers16193335","volume":"16","author":"PGBL Ryan Munnings","year":"2024","unstructured":"Ryan Munnings PGBL. Evolution of Liquid Biopsies for Detecting Pancreatic Cancer. Cancers (Basel). 2024;16:3335. https:\/\/doi.org\/10.3390\/cancers16193335.","journal-title":"Cancers (Basel)"},{"key":"2201_CR119","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cytogfr.2023.07.006","volume":"73","author":"W Guo","year":"2023","unstructured":"Guo W, Ying P, Ma R, et al. Liquid biopsy analysis of lipometabolic exosomes in pancreatic cancer. Cytokine Growth Factor Rev. 2023;73:69\u201377. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.07.006.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2201_CR120","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3377","author":"Y Meng","year":"2025","unstructured":"Meng Y, Wu F, Kwak S, et al. Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. JAMA Oncol. 2025. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3377.","journal-title":"JAMA Oncol"},{"key":"2201_CR121","doi-asserted-by":"publisher","first-page":"1782960","DOI":"10.3389\/fimmu.2026.1782960","volume":"17","author":"J Yan","year":"2026","unstructured":"Yan J, Ou H, Wang S, et al. Overcoming multidimensional immunotherapy resistance in PDAC: from microenvironment to clinic. Front Immunol. 2026;17:1782960. https:\/\/doi.org\/10.3389\/fimmu.2026.1782960.","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02201-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02201-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02201-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:32:44Z","timestamp":1785807164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02201-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2201"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02201-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"285"}}